Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single Microdose Trial of [68Ga]Ga-R54 PET Tracer in Advanced Solid Tumors and Multiple Myeloma
NCT07577206Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [68Ga]Ga-R54 in solid tumor and multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoints: Maximum Standardized Uptake Value at Day 1 and Pharmacokinetics of [68Ga]Ga-R54 at Day 1. Started Jan 2025; status: recruiting.
02
Drugs
[68Ga]Ga-R54
03
Conditions
solid tumormultiple myeloma (MM)
Beyond the preview
Go deeper on NCT07577206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07577206.